Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NET-02: Nal-IRI/5-FU vs Docetaxel in NEC
NCT03837977Phase 2Completed
- Sponsor
- The Christie
- Start
- Nov 2018
- Primary completion
- Nov 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nanoliposomal irinotecan in extrapulmonary neuroendocrine carcinoma (EPNEC) (2 arms), sponsored by The Christie. Primary endpoint: Progression-Free Survival Rate at 6 months. Started Nov 2018; status: completed.
02
Drugs
nanoliposomal irinotecan
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT03837977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837977.